-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026-
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Medical%20lab%20microscope%20chemistry%20biology%20test%20by%20Shutter2U%20via%20Adobe%20Stock.jpeg)
/Apple%20logo%20-%20by%20Pexels%20via%20Pixabay.jpg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/An%20aerial%20view%20of%20a%20data%20center%20cooling%20system%20by%20Sepia100%20via%20Adobe%20Stock.jpeg)